Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Presents Preclinical Data on Tri-specific (PD-L1, 4-1BB, HSA) mAb

publication date: Apr 13, 2022

Suzhou CStone Pharma released preclinical data on a tri-specific antibody-based molecule that targets PD-L1, 4-1BB and human serum albumin. It described the molecule, CS2006/NM21-1480, as a broadly acting next-gen anti-PD-1/PD-L1 cancer immunotherapy that will serve as a novel backbone for tumor-specific combination therapies. By targeting the immune co-stimulatory receptor 4-1BB, the molecule is expected to bind and activate T cells only when binding PD-L1 on the surface of tumor cells. CStone has started Phase I trials of the candidate in the US, Taiwan and China. More details....

Stock Symbols: (HK: 2616)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital